Skip to main content
SpringerLink
Log in

Febuxostat is superior to allopurinol in delaying the progression of renal impairment in patients with chronic kidney disease and hyperuricemia

  • Nephrology - Original Paper
  • Published:
International Urology and Nephrology Aims and scope Submit manuscript

Abstract

Purpose

This study aimed to compare efficacy of renal-protective function between febuxostat and allopurinol in patients with chronic kidney disease (CKD) and hyperuricemia (HUA).

Methods

Totally 152 CKD stage 2–3 patients complicated with HUA were recruited. According to their uric acid-lowering therapy, there were 67 patients included in febuxostat group and 85 in allopurinol group, respectively. Estimated glomerular filtration rate (eGFR), serum creatinine (Scr), 24-h proteinuria, serum uric acid (SUA) were measured at M0, M1, M3 and M6 after the treatment. Primary outcome was proportion of patients showing ≥ 10% decline in eGFR from baseline at M6.

Results

The eGFR at M6 was numerically higher at M6 and eGFR change (M6–M0) was increased in febuxostat group compared with allopurinol group. Most importantly, the proportion of patients showing a ≥ 10% decline in eGFR from baseline at M6 was reduced in febuxostat group compared with allopurinol group. Multivariate logistic regression analyses further validated that febuxostat vs. allopurinol was an independent predictor for reduced risk of eGFR decline ≥ 10% from baseline. Besides, SUA change (M6–M0) was decreased, but Scr change (M6–M0) and 24-h proteinuria change (M6–M0) were similar in febuxostat group compared with allopurinol group.

Conclusions

Febuxostat presents a superior effect in delaying renal impairment progression compared with allopurinol in CKD patients complicated with HUA.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Zhang L, Wang F, Wang L, Wang W, Liu B, Liu J, Chen M, He Q, Liao Y, Yu X, Chen N, Zhang JE, Hu Z, Liu F, Hong D, Ma L, Liu H, Zhou X, Chen J, Pan L, Chen W, Wang W, Li X, Wang H (2012) Prevalence of chronic kidney disease in China: a cross-sectional survey. Lancet 379(9818):815–822

    Article  Google Scholar 

  2. Shen Q, Jin W, Ji S, Chen X, Zhao X, Behera TR (2019) The association between socioeconomic status and prevalence of chronic kidney disease: a cross-sectional study among rural residents in eastern China. Medicine (Baltimore) 98(11):e14822

    Article  Google Scholar 

  3. Fan S, Zhang P, Wang AY, Wang X, Wang L, Li G, Hong D (2019) Hyperuricemia and its related histopathological features on renal biopsy. BMC Nephrol 20(1):95

    Article  Google Scholar 

  4. Garofalo C, De Stefano T, Vita C, Vinci G, Balia F, Nettuno F, Scarpati L, Sguazzo A, Sagliocchi A, Pacilio M, Minutolo R, De Nicola L, Borrelli S (2018) Hyperuricaemia and chronic kidney disease. G Ital Nefrol 35:1

    Google Scholar 

  5. Li L, Yang C, Zhao Y, Zeng X, Liu F, Fu P (2014) Is hyperuricemia an independent risk factor for new-onset chronic kidney disease?: a systematic review and meta-analysis based on observational cohort studies. BMC Nephrol 15:122

    Article  Google Scholar 

  6. Hahn K, Kanbay M, Lanaspa MA, Johnson RJ, Ejaz AA (2017) Serum uric acid and acute kidney injury: a mini review. J Adv Res 8(5):529–536

    Article  CAS  Google Scholar 

  7. Chinchilla SP, Urionaguena I, Perez-Ruiz F (2016) Febuxostat for the chronic management of hyperuricemia in patients with gout. Expert Rev Clin Pharmacol 9(5):665–673

    Article  CAS  Google Scholar 

  8. Levy G, Shi JM, Cheetham TC, Rashid N (2018) Urate-lowering therapy in moderate to severe chronic kidney disease. Perm J 22:17–142

    PubMed  PubMed Central  Google Scholar 

  9. Shahid H, Singh JA (2015) Investigational drugs for hyperuricemia. Expert Opin Investig Drugs 24(8):1013–1030

    Article  CAS  Google Scholar 

  10. Liu X, Liu K, Sun Q, Wang Y, Meng J, Xu Z, Shi Z (2018) Efficacy and safety of febuxostat for treating hyperuricemia in patients with chronic kidney disease and in renal transplant recipients: a systematic review and meta-analysis. Exp Ther Med 16(3):1859–1865

    PubMed  PubMed Central  Google Scholar 

  11. Richette P, Doherty M, Pascual E, Barskova V, Becce F, Castaneda-Sanabria J, Coyfish M, Guillo S, Jansen TL, Janssens H, Liote F, Mallen C, Nuki G, Perez-Ruiz F, Pimentao J, Punzi L, Pywell T, So A, Tausche AK, Uhlig T, Zavada J, Zhang W, Tubach F, Bardin T (2017) 2016 updated EULAR evidence-based recommendations for the management of gout. Ann Rheum Dis 76(1):29–42

    Article  CAS  Google Scholar 

  12. Yamaguchi A, Harada M, Yamada Y, Hashimoto K, Kamijo Y (2017) Identification of chronic kidney disease patient characteristics influencing the renoprotective effects of febuxostat therapy: a retrospective follow-up study. BMC Nephrol 18(1):162

    Article  Google Scholar 

  13. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group (2013) KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int 3(1):1–150

    Article  Google Scholar 

  14. Multidisciplinary Expert Task Force on H, Related D (2017) Chinese multidisciplinary expert consensus on the diagnosis and treatment of hyperuricemia and related diseases. Chin Med J (Engl) 130(20):2473–2488

    Article  Google Scholar 

  15. Levey AS, de Jong PE, Coresh J, El Nahas M, Astor BC, Matsushita K, Gansevoort RT, Kasiske BL, Eckardt KU (2011) The definition, classification, and prognosis of chronic kidney disease: a KDIGO Controversies Conference report. Kidney Int 80(1):17–28

    Article  Google Scholar 

  16. Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF 3rd, Feldman HI, Kusek JW, Eggers P, Van Lente F, Greene T, Coresh J, Ckd EPI (2009) A new equation to estimate glomerular filtration rate. Ann Intern Med 150(9):604–612

    Article  Google Scholar 

  17. Sudchada P, Laehn S (2016) Comparisons of GFR estimation using the CKD Epidemiology Collaboration (CKD-EPI) equation and other creatinine-based equations in Asian population: a systematic review. Int Urol Nephrol 48(9):1511–1517

    Article  CAS  Google Scholar 

  18. Sircar D, Chatterjee S, Waikhom R, Golay V, Raychaudhury A, Chatterjee S, Pandey R (2015) Efficacy of febuxostat for slowing the GFR decline in patients with CKD and asymptomatic hyperuricemia: a 6-month, double-blind, randomized, placebo-controlled trial. Am J Kidney Dis 66(6):945–950

    Article  CAS  Google Scholar 

  19. Noto N, Kamiyama H, Karasawa K, Ayusawa M, Sumitomo N, Okada T, Takahashi S (2014) Long-term prognostic impact of dobutamine stress echocardiography in patients with Kawasaki disease and coronary artery lesions: a 15-year follow-up study. J Am Coll Cardiol 63(4):337–344

    Article  Google Scholar 

  20. Pisano A, Cernaro V, Gembillo G, D’Arrigo G, Buemi M, Bolignano D (2017) Xanthine oxidase inhibitors for improving renal function in chronic kidney disease patients: an updated systematic review and meta-analysis. Int J Mol Sci 18:11

    Article  Google Scholar 

  21. Mazzali M, Hughes J, Kim YG, Jefferson JA, Kang DH, Gordon KL, Lan HY, Kivlighn S, Johnson RJ (2001) Elevated uric acid increases blood pressure in the rat by a novel crystal-independent mechanism. Hypertension 38(5):1101–1106

    Article  CAS  Google Scholar 

  22. Siu YP, Leung KT, Tong MK, Kwan TH (2006) Use of allopurinol in slowing the progression of renal disease through its ability to lower serum uric acid level. Am J Kidney Dis 47(1):51–59

    Article  CAS  Google Scholar 

  23. Chen C, Lu JM, Yao Q (2016) Hyperuricemia-related diseases and xanthine oxidoreductase (XOR) inhibitors: an overview. Med Sci Monit 22:2501–2512

    Article  CAS  Google Scholar 

  24. Sarvepalli PS, Fatima M, Quadri AK, Taher AR, Habeeb A, Amreen F, Parveen BN, Rajaram KG (2018) Study of therapeutic efficacy of febuxostat in chronic kidney disease stage IIIA to stage VD. Saudi J Kidney Dis Transpl 29(5):1050–1056

    Article  Google Scholar 

  25. Kimura K, Hosoya T, Uchida S, Inaba M, Makino H, Maruyama S, Ito S, Yamamoto T, Tomino Y, Ohno I, Shibagaki Y, Iimuro S, Imai N, Kuwabara M, Hayakawa H, Ohtsu H, Ohashi Y, Investigators FS (2018) Febuxostat therapy for patients with stage 3 CKD and asymptomatic hyperuricemia: a randomized trial. Am J Kidney Dis 72(6):798–810

    Article  CAS  Google Scholar 

  26. Hu M, Tomlinson B (2008) Febuxostat in the management of hyperuricemia and chronic gout: a review. Ther Clin Risk Manag 4(6):1209–1220

    CAS  PubMed  PubMed Central  Google Scholar 

  27. Sezai A, Soma M, Nakata K, Osaka S, Ishii Y, Yaoita H, Hata H, Shiono M (2015) Comparison of febuxostat and allopurinol for hyperuricemia in cardiac surgery patients with chronic kidney disease (NU-FLASH trial for CKD). J Cardiol 66(4):298–303

    Article  Google Scholar 

  28. Ito H, Antoku S, Abe M, Omoto T, Shinozaki M, Nishio S, Mifune M, Togane M, Nakata M, Yamashita T (2016) Comparison of the renoprotective effect of febuxostat for the treatment of hyperuricemia between patients with and without type 2 diabetes mellitus: a retrospective observational study. Intern Med 55(22):3247–3256

    Article  CAS  Google Scholar 

  29. Lee JW, Lee KH (2019) Comparison of renoprotective effects of febuxostat and allopurinol in hyperuricemic patients with chronic kidney disease. Int Urol Nephrol 51(3):467–473

    Article  CAS  Google Scholar 

  30. Liu X, Wang H, Ma R, Shao L, Zhang W, Jiang W, Luo C, Zhai T, Xu Y (2019) The urate-lowering efficacy and safety of febuxostat versus allopurinol in Chinese patients with asymptomatic hyperuricemia and with chronic kidney disease stages 3-5. Clin Exp Nephrol 23(3):362–370

    Article  CAS  Google Scholar 

  31. Chou HW, Chiu HT, Tsai CW, Ting IW, Yeh HC, Huang HC, Kuo CC, Group CKR (2018) Comparative effectiveness of allopurinol, febuxostat and benzbromarone on renal function in chronic kidney disease patients with hyperuricemia: a 13-year inception cohort study. Nephrol Dial Transplant 33(9):1620–1627

    CAS  PubMed  Google Scholar 

  32. Tsai CW, Lin SY, Kuo CC, Huang CC (2017) Serum uric acid and progression of kidney disease: a longitudinal analysis and mini-review. PLoS One 12(1):e0170393

    Article  Google Scholar 

  33. Demir AD, Goknar N, Oktem F, Ozkaya E, Yazici M, Torun E, Vehapoglu A, Kucukkoc M (2016) Renal tubular function and urinary N-acetyl-beta-d-glucosaminidase and kidney injury molecule-1 levels in asthmatic children. Int J Immunopathol Pharmacol 29(4):626–631

    Article  CAS  Google Scholar 

  34. Bratel T, Ljungman S, Runold M, Stenvinkel P (2003) Renal function in hypoxaemic chronic obstructive pulmonary disease: effects of long-term oxygen treatment. Respir Med 97(4):308–316

    Article  CAS  Google Scholar 

Download references

Author information

Author notes

  1. Xin Zhang and Dapeng Wan contributed equally to this work.

Authors and Affiliations

  1. Department of Nephrology, The Fifth Hospital of Wuhan, 122 Xianzheng Street, Wuhan, 430050, China

    Xin Zhang, Guosheng Yang, Qingping Peng & Xiaohui Wang

  2. Department of Clinical Laboratory, Wuhan Fourth Hospital, Puai Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China

    Dapeng Wan

Authors
  1. Xin Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Dapeng Wan
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Guosheng Yang
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Qingping Peng
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Xiaohui Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Xiaohui Wang.

Ethics declarations

Conflict of interest

No conflicts of interest, financial or otherwise, are declared by the authors.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Supplementary material 1 (DOCX 19 kb)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Zhang, X., Wan, D., Yang, G. et al. Febuxostat is superior to allopurinol in delaying the progression of renal impairment in patients with chronic kidney disease and hyperuricemia. Int Urol Nephrol 51, 2273–2283 (2019). https://doi.org/10.1007/s11255-019-02318-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11255-019-02318-8

Keywords

Search

Navigation